More on the impact of American Academy of Pediatrics palivizumab guidance for infants with respiratory syncytial virus infection
- PMID: 31204022
- DOI: 10.1016/j.jpeds.2019.05.044
More on the impact of American Academy of Pediatrics palivizumab guidance for infants with respiratory syncytial virus infection
Comment in
-
Reply.J Pediatr. 2019 Sep;212:247-248. doi: 10.1016/j.jpeds.2019.05.045. Epub 2019 Jun 14. J Pediatr. 2019. PMID: 31204023 No abstract available.
Comment on
-
Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age.J Pediatr. 2019 Jun;209:125-129. doi: 10.1016/j.jpeds.2019.02.020. Epub 2019 Apr 2. J Pediatr. 2019. PMID: 30952507
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical